|
郑文云,教授,博士生导师、药物科学系主任
2024欧洲杯官方网站的联系方式:
通讯地址:上海市梅陇路130号318信箱,邮编200237
电话:(021)64253980;电邮:
个人简历:
郑文云,教授,理学博士,华东理工大学 药学院/上海市新药设计重点实验室,博士生导师,上海市优秀青年骨干教师。2006毕业于沈阳药科大学获博士学位,师从杨胜利院士;2013年美国明尼苏达大学(university of minnesota)访问留学一年。
研究领域\方向、学术兼职和荣誉奖励:
研究领域:生物药物\\药理药效与药剂学;研究方向:抗肿瘤新药研发、评价及转载系统研究。
学术兼职:biochemistry and molecular biology编委;drug design, research and development编委;
biomedcine & pharmacotherapy特约审稿人;上海生物工程学会、中国生物技术药物学会会员。
荣誉奖励:2007年获上海市优秀青年骨干教师荣誉称号;
2016年上海科技发明奖(生物医药)三等奖;
2015年第28届上海市优秀科技发明选拔赛(银奖);
2015年第28届上海市优秀科技发明选拔赛(铜奖);
2016年校级优秀教育教学成果奖二等奖。
科研项目情况
承担国家自然科学基金,上海市“科技创新”行动计划项目,教育部博士点基金和上海优秀青年骨干教师科研基金项目等,参与国家重点研发计划,国家“十一五”“新药创制”重大专项,教育部交叉学科与重大项目培育基金项目,上海市科技创新行动计划生物医药领域科技支撑项目等。近年主持的部分主要科研项目:
1.国家自然科学基金,鲨鱼天然抗体ignar超稳定分子机制及其特异性纳米抗体(nb/pd-l1)筛选鉴定与抗肺癌活性研究;
2.国家自然科学基金,胞外分泌型人巯基氧化酶1(es-hqsox1b)剪接体功能及其生物药学意义探索;
3.上海市“科技创新”行动计划项目,抗肿瘤重组蛋白tmsm临床前药剂学与药理机制研究;
4.教育部博士点基金项目,分泌型hqsox1b在细胞基质形成中的机制研究。
5.企业合作项目3项。
代表性论文:
1. wei guo, xingyuan ma, yunhui fu, chang liu, qiuli liu, fabiao hu, hui miao,tong zhang, yuping liu, myong hun han, fang you, yi yang* and wenyun zheng*.discovering and characterizing of survivin dominant negative mutants with stronger pro-apoptotic activity on cancer cells and cscs.front. oncol.2021,11:635233.
2. jifannie, xingyuanma,fabiaohu,huimiao,xinfeng,peiwenzhang,myong hunhan,fangyou,yiyang,wenlianzhang,wenyunzheng*. designing and constructing a phage display synthesized single domain antibodies library based on camel vhh frame for screening and identifying humanized tnf-α-specific nanobody,biomedicine & pharmacotherapy2021 doi:
3. zhangting zhao, xingyuan ma, ruihuan zhang, fabiao hu, tong zhang, yuping liu, myong hun han, fang you, yi yang⁎, wenyun zheng*.a novel liposome-polymer hybrid nanoparticles delivering a multi-epitope 2 self-replication dna vaccine and its preliminary immune evaluation in 3 experimental animals. nanomedicine: nanotechnology, biology, and medicine, 2020 ,
4. ling-ke liu, xiao-xiao chen, rui-lin gao, ke-jian wang, wen-yun zheng∗, hai-peng liu∗ ,a cytokine receptor domeless promotes white spot syndrome virus infection via jak/stat signaling pathway in red claw crayfish cherax quadricarinatus, developmental and comparative immunology,2020,111:103749
5. fabiao hu, ruihuan zhang, wei guo, ting yan, xiujuan he, fengzhi hu, fuzheng ren, xingyuan ma*, jiandu lei, wenyun zheng* pegylated-plga nanoparticles coated with ph responsive tannic acid-fe(iii) complexes for reduced premature doxorubicin release and enhanced targeting in breast cancer,mol pharmaceut2020.doi: 10.1021/acs..0c00321.
6. fabiao hu,ting yan, wei guo, qiuli liu, myong hun han, chang liu,yuping liu, wenyun zheng*, fang you*, yi yang, wenliang zhang and xingyuan ma*. multiple targeting strategies achieve novel protein drug deliver into cancer cells to proapoptosis lung cancer cell by precisely inhibiting surviving. nanoscale, 2020, 12,10623–10638
7. wenpeng wang, wenyun zheng, fengzhi hu, xiujuan he, dong wu, wenliang zhang, haipeng liu,and xingyuan ma*,enhanced biosynthesis performance of heterologous proteins in cho-k1 cells using crispr-cas9,acs synth. biol. 2018, 7, 1259−1268
8. chen xx, li yy, chang xj, xie xl, liang yt, wang kj, zheng wy*, liu hp*. a cqferritin protein inhibits white spot syndrome virus infection via regulating iron ions in red claw crayfish cherax quadricarinatus. dev comp immunol. 2018 ;82:104-112.
9. fabiao hu, daxia pan, wenyun zheng*, xiujuan he, fuzheng ren, yiming lu, xingyuan ma. elucidating respective functions of two domains bir and c- helix of human iap survivin for precise targeted regulating mitotic cycleapoptosis and autophagy of cancer cells. oncotarget. 2017,8(69):113687-113700
10. di liu, fabiao hu, wenpeng wang, dong wu, xiujuan he, wenyun zheng*, haipeng liu*, xingyuan ma* elucidating bottlenecks of the efficient preparation of an ab5-hexamer mucosal adjuvant protein ltm by genetic engineering. journal of microbiology and biotechnology. 2017, 27(8), 1461-147.
11. xingyuan ma, yi zhang, yanyan kang, linfeng li,wenyun zheng*. a recombinant protein tmsm(t34a) can inhibit proliferation and proapoptosis to breast cancer stem cells(bcscs) by down-regulating the expression of cyclin d1.biomed pharmacother. 2016, 23(84):373-381
12. xingyuan ma, nanjing lin, yanyan kang, linfeng li,wenyun zheng*, screening and identification of highly specific mcabs for discovering novel biomarkers of bone marrow stromal cells,monoclonal antibody in immunodiagnosis and immunotherapy,2016, 35(4): 199-211.
13. liqun wang, yanyan kang,wenyun zheng *, linfengli, lei shi, xingyuan ma. effect on apoptosis and cell cycle of recombinant double negative dominant mutation survivin (t34/117a) in breast cancer cell b-cap-37.biomedicine & pharmacotherapy, 2014, 68(3): 277–284
14. nanjing lin#,wenyun zheng#, linfeng li ,hui liu, tianwen wang, ping wang, xingyuan ma,. a novel system enhancing the endosomal escapes of peptides promotes bak bh3 peptide inducing apoptosis in lung cancer a549 cells. targeted oncology. 2014, 9(2): 163-170(coauthor)
15. wenyun zheng, wenyao zhang, wei hu, and yi yang,exploring the smallest active fragment of hsqsox1b and discovery of a highly efficient oxidative engine, plos one. 2012,7 (7): e40935. doi:10.1371
16. yuxin xu#,wenyun zheng#,tianwen wang, ping wang, ling zhu, xingyuan ma*., genetic protein tmsm(t34a) enhances sensitivity of chemotherapy to breast cancer cell lines as a synergistic drug to doxorubicin. biomedicine & pharmacotherapy, 2012, 66(5): 368-372 (#coauthor)
17. wenyun zheng,yanyan chu, qin yin, charles yang, wenyao zhang, yun tang, yi yang. crucial effect of the first cxxc motif of human qsox 1b on the activity to different substrates. journal of biochemistry. 2011, 149(3):293-300
18. wenyun zheng, yanyan kang, linfeng li, yuxin xu, xingyuan ma, levels of effectiveness of gene therapies targeting survivin and its splice variants in human breast cancer cells.drug discoveries & therapeutics. 2011, 5(6):293-2989.
地址:上海市徐汇区梅陇路130号 邮编:200237
2024欧洲杯官方网站的版权所有 © 2023 华东理工大学药学院 |